Pieter Cullis

Pieter Rutter Cullis is a Canadian physicist and biochemist known for his contributions to the field of lipid nanoparticles (LNP). Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval by the US Food and Drug Agency (FDA), the European Medicines Agency, and Health Canada.

Cullis has also co-founded eleven biotechnology companies that now employ over 400 people, has published over 400 scientific articles (h-index 138) and is an inventor on over 100 patents. Companies he has co-founded include Acuitas Therapeutics, Integrated Nanotherapeutics, Precision NanoSystems, and NanoVation Therapeutics. He has also co-founded and has been the Founding Scientific Director of two National Centre of Excellence networks: the Centre for Drug Research and Development (now AdMare) in 2004 and the NanoMedicines Innovation Network in 2019. These not-for-profit networks are aimed at translating basic research in the life sciences into commercially viable products.

Two recently approved drugs that are enabled by LNP delivery systems devised by Cullis, members of his UBC laboratory, and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is Comirnaty, the COVID-19 mRNA vaccine developed by Pfizer/BioNTech that has received regulatory approval in many jurisdictions including Canada, the USA, the UK and Europe. Comirnaty has played a major role in containing the global COVID-19 pandemic with approximately 6B doses administered worldwide in 2021 and 2022. Provided by Wikipedia